1. Home
  2. ADMA

as of 11-20-2026 3:45pm EST

$13.26
$0.07
-0.53%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Founded: 2004 Country:
United States
United States
Employees: N/A City: RAMSEY
Market Cap: 2.5B IPO Year: 2012
Target Price: $18.00 AVG Volume (30 days): 3.8M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.57 EPS Growth: -25.93
52 Week Low/High: $7.21 - $20.46 Next Earning Date: 11-04-2026
Revenue: $42,219,783 Revenue Growth: 43.85%
Revenue Growth (this year): 4.49% Revenue Growth (next year): 14.91%
P/E Ratio: 23.39 Index:
Free Cash Flow: 27.8M FCF Growth: +226.36%

Stock Insider Trading Activity of ADMA Biologics Inc (ADMA)

Grossman Adam S

President and CEO

Sell
ADMA Nov 5, 2026

Avg Cost/Share

$12.00

Shares

147,000

Total Value

$1,764,000.00

Owned After

2,112,777

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 4, 2026 · 100% conf.

AI Prediction BUY

1D

+7.78%

$11.97

Act: +26.05%

5D

+11.02%

$12.33

20D

+13.07%

$12.56

Price: $11.11 Prob +5D: 100% AUC: 1.000
0001140361-26-041959

EX-99.1

2 ef20084542_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year

3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year

3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year

3Q 2026 Adjusted Net Income(1) of $51.1 Million, Increasing 31% Year-over-Year

3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year

3Q 2026 Adjusted Basic EPS(2) of $0.23, Increasing 44% Year-over-Year

3Q 2026 Adjusted EBITDA(3) of $77.3 Million, Increasing 32% Year-over-Year

3Q 2026 Gross Margin of 71%, Expanding Approximately 1,450 Basis Points Year-over-Year

Expanding ASCENIV Real-World Health Outcomes Evidence Strengthens Commercial Differentiation

Robust Cash Generation, Operating Leverage and Share Repurchases Support Stockholder Value

Encouraging Regulatory Feedback Received from SG-001 Pre-IND Meeting Package

Reiterates FY2026 Revenue Guidance; Increases Adjusted Earnings Outlook

RAMSEY, N.J. and BOCA RATON, FL, November 4, 2026 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its third quarter 2026 financial results and provided a business update.

“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth,” said Adam Grossman, President and Chief Executive Officer of ADMA. “ASCENIV revenue increased 31% year-over-year, driven by expanding physician adoption, new patient starts and growing end-user utilization. Favorable demand trends have continued into the fourth quarter, highlighting the durability of ASCENIV’s growth trajectory and significant remaining market opportunity. We are also encouraged by signs of stabilization in underlying BIVIGAM utilization, despite competitive pressures in the standard immune globulin market. Together with expanding margins and substantial per-share earnings growth, we believe these trends demonstrate the scalability and increasing profitability of our business.”

Mr. Grossman continued, “Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption. With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation. We are reiterating our full-year revenue outlook while increasing our minimum expectations for Adjusted Net Income and Adjusted EBITDA and continue to advance SG-001 as a potential additional long-term growth opportunity. We are also encouraged by the constructive FDA feedback recently received on our SG-001 pre-IND meeting package, which we believe represents an important milestone for the program. Notably, we received constructive feedback from the FDA regarding the proposed clinical development strategy, including key elements of the planned clinical study. Based on the FDA’s feedback, we intend to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission. The FDA also indicated that our proposed assay would be acceptable for product testing, subject to appropriate validation. We believe this feedback supports a potentially efficient development pathway that leverages ADMA’s established manufacturing capabilities and clinical development experience as we advance SG-001 toward clinical trials.”

1

Reiterated FY2026 Revenue Guidance and Increased Adjusted Earnings Outlook

●

FY2026 total revenue expected to be at least $530 million

●

FY2026 Adjusted Net Income expected to be at least $180 million

●

FY2026 Adjusted EBITDA expected to be at least $275 million

ADMA’s FY2026 outlook reflects continued ASCENIV commercial momentum and conservative assumptions for competitive conditions in the U.S. standard immune globulin market. Favorable ASCENIV utilization trends have continued into the fourth quarter, while underlying BIVIGAM utilization has shown encouraging signs of stabilization.

Third Quarter Commercial and Operational Highlights

●

ASCENIV Growth Accelerated and Momentum Extended Into the Fourth Quarter. ASCENIV revenue in the third quarter reached $124.7 million, increasing 31% year-over-year and 21% sequentially, driven by expanding physician adoption, new patient starts and growing end-user utilization. Favorable pull-through trends continued into the fourth quarter, supporting confidence in the product’s growth trajectory.

●

BIVIGAM Utilization Showed Encouraging Signs of Stabilization. Third quarter BIVIGAM revenue was $15.4 million, compared with $19.4 million in the second

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 5, 2026 · 100% conf.

AI Prediction BUY

1D

+7.73%

$9.98

Act: +8.99%

5D

+11.40%

$10.32

Act: +5.62%

20D

+13.82%

$10.54

Price: $9.26 Prob +5D: 100% AUC: 1.000
0001140361-26-031423

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786388950.cfa5ad5e

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 6, 2026 · 100% conf.

AI Prediction SELL

1D

-5.22%

$9.52

Act: -15.68%

5D

-5.85%

$9.46

Act: -15.38%

20D

-6.82%

$9.36

Act: -20.56%

Price: $10.04 Prob +5D: 0% AUC: 1.000
0001140361-26-019295

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784333750.ccb3c944

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: